Views & Analysis Recent trends in ANDA litigation Sheila Swaroop and Kaitlin Heinen examine the findings of a recent report.
News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
